ANAB AnaptysBio, Inc.
Healthcare$57.77-3.25%ClosedMarket Cap: $2.49B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
134.40
P/S
11.08
EV/EBITDA
48.82
DCF Value
$-311.13
FCF Yield
0.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
116.4%
Operating Margin
17.6%
Net Margin
-11.5%
ROE
442.9%
ROA
-8.1%
ROIC
14.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $25.6M | 97.6% | $-34.6M | $-52.9M | $— | — |
| Q4 null | $108.2M | 199.8% | $66.9M | $49.6M | $— | — |
| FY null | $234.6M | 99.0% | $47.9M | $-13.2M | $— | — |
| Q3 null | $76.3M | 58.8% | $34.7M | $15.1M | $— | — |
| Q2 null | $22.3M | -69.9% | $-26.2M | $-38.6M | $— | — |
| Q1 null | $27.8M | -48.3% | $-27.5M | $-39.3M | $— | — |
| Q4 null | $43.1M | 1.2% | $-9.7M | $-21.8M | $— | — |
| FY null | $91.3M | -79.5% | $-114.9M | $-145.2M | $— | — |
| Q3 null | $30.0M | -40.6% | $-22.8M | $-32.9M | $— | — |
| Q2 null | $11.0M | -282.8% | $-40.3M | $-46.7M | $— | — |
| Q1 null | $7.2M | -416.0% | $-42.2M | $-43.9M | $— | — |
| Q4 2023 | $9.0M | -272.3% | $-42.1M | $-42.2M | $-1.57 | — |